FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of biotechnology. The claimed invention relates to the field of modulation of enzymatic activity by application of interaction between a molecular chaperone Hsp70 and lysosomal phospholipid bis(monoacylglycero)phosphate (BMP). The invention can be used in medicine.
EFFECT: interaction of Hsp70-BMP modulates activity of lysosomal compartment enzymes, interacting with BMP, therefore the claimed invention represents means of reversing pathology of lysosomal storage diseases.
21 cl, 16 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF HSP70 AS ENZYME ACTIVITY REGULATOR | 2009 |
|
RU2571946C2 |
| GENETIC CONSTRUCT FOR EXPRESSION IN LYSOSOMES OF MAMMALIAN CELLS OF RHODOPSIN NsXeR FROM ORGANISM NANOHALOARCHAEON NANOSALINA, WHICH ENABLES TO INCREASE pH OF LYSOSOMES | 2023 |
|
RU2820973C1 |
| TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOF | 2013 |
|
RU2680581C2 |
| INTRAVENTRICULAR DELIVERY OF ENZYMES IN LYSOSOMAL STORAGE DISEASES | 2014 |
|
RU2665381C2 |
| INTRAVENTRICULAR DELIVERY OF ENZYMES IN CASE OF LYSOSOMAL STORAGE DISEASES | 2007 |
|
RU2529830C2 |
| METHOD FOR IDENTIFYING COMPOUNDS FOR TREATING CANCER | 2010 |
|
RU2575828C2 |
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE | 2011 |
|
RU2660348C2 |
| METHODS AND COMPOSITIONS FOR DELIVERY OF IDURONATE-2-SULPHATASE TO CNS | 2011 |
|
RU2774112C2 |
| THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS | 2017 |
|
RU2751235C2 |
| COMPOUND CONTAINING THERAPEUTIC ENZYME AND TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING LINKER | 2022 |
|
RU2811100C1 |
